Suppr超能文献

相似文献

1
Diagnostic value of PIVKA-II and alpha-fetoprotein in hepatitis B virus-associated hepatocellular carcinoma.
World J Gastroenterol. 2015 Apr 7;21(13):3928-35. doi: 10.3748/wjg.v21.i13.3928.
2
Combined use of AFP, PIVKA-II, and AFP-L3 as tumor markers enhances diagnostic accuracy for hepatocellular carcinoma in cirrhotic patients.
Scand J Gastroenterol. 2016 Mar;51(3):344-53. doi: 10.3109/00365521.2015.1082190. Epub 2015 Sep 4.
3
Risk of hepatocellular carcinoma in HBV cirrhotic patients assessed by the combination of miR-122, AFP and PIVKA-II.
Panminerva Med. 2017 Dec;59(4):283-289. doi: 10.23736/S0031-0808.17.03353-5. Epub 2017 Jun 23.
7
Could serotonin be a potential marker for hepatocellular carcinoma? A prospective single-center observational study.
Eur J Gastroenterol Hepatol. 2016 May;28(5):599-605. doi: 10.1097/MEG.0000000000000569.
8
Protein induced by vitamin K absence or antagonist-II (PIVKA-II) specifically increased in Italian hepatocellular carcinoma patients.
Scand J Gastroenterol. 2016 Oct;51(10):1257-62. doi: 10.1080/00365521.2016.1183705. Epub 2016 May 26.

引用本文的文献

1
Application of biological big data and radiomics in hepatocellular carcinoma.
ILIVER. 2023 Feb 4;2(1):41-49. doi: 10.1016/j.iliver.2023.01.003. eCollection 2023 Mar.
2
Predictive Factors and Nomogram (MAP-BNP) for Post Stereotactic Body Radiotherapy Survival in Advanced Hepatocellular Carcinoma Patients.
J Clin Exp Hepatol. 2025 Sep-Oct;15(5):102555. doi: 10.1016/j.jceh.2025.102555. Epub 2025 Mar 28.
3
Strategies for discovering novel hepatocellular carcinoma biomarkers.
World J Hepatol. 2025 Feb 27;17(2):101201. doi: 10.4254/wjh.v17.i2.101201.
6
Novel biomarkers for monitoring and management of hepatocellular carcinoma.
Cancer Cell Int. 2024 Dec 24;24(1):428. doi: 10.1186/s12935-024-03600-1.
9
Biomarkers for diagnosis and therapeutic options in hepatocellular carcinoma.
Mol Cancer. 2024 Sep 6;23(1):189. doi: 10.1186/s12943-024-02101-z.
10
Redefining HCC Surveillance in India: A Call for Innovative and Inclusive Strategies.
J Clin Exp Hepatol. 2024 Nov-Dec;14(6):101474. doi: 10.1016/j.jceh.2024.101474. Epub 2024 Jun 25.

本文引用的文献

1
EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma.
J Hepatol. 2012 Apr;56(4):908-43. doi: 10.1016/j.jhep.2011.12.001.
2
Management of hepatocellular carcinoma: an update.
Hepatology. 2011 Mar;53(3):1020-2. doi: 10.1002/hep.24199.
3
Clinical and molecular insights into the hepatocellular carcinoma tumour marker des-γ-carboxyprothrombin.
Liver Int. 2011 Jan;31(1):22-35. doi: 10.1111/j.1478-3231.2010.02348.x. Epub 2010 Sep 27.
5
Serum markers of hepatocellular carcinoma.
Dig Dis Sci. 2010 Oct;55(10):2744-55. doi: 10.1007/s10620-010-1184-7. Epub 2010 Mar 26.
7
Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma.
Gastroenterology. 2009 Jul;137(1):110-8. doi: 10.1053/j.gastro.2009.04.005. Epub 2009 Apr 9.
8
Des-gamma-carboxyprothrombin, alpha-fetoprotein and AFP-L3 in patients with chronic hepatitis, cirrhosis and hepatocellular carcinoma.
J Gastroenterol Hepatol. 2008 Oct;23(10):1541-8. doi: 10.1111/j.1440-1746.2008.05395.x. Epub 2008 Apr 19.
9
Surveillance for hepatocellular carcinoma in patients with cirrhosis improves outcome.
Am J Med. 2008 Feb;121(2):119-26. doi: 10.1016/j.amjmed.2007.09.020.
10
Sensitivity and specificity of des-gamma-carboxy prothrombin for diagnosis of patients with hepatocellular carcinomas varies according to tumor size.
Am J Gastroenterol. 2006 Sep;101(9):2038-43. doi: 10.1111/j.1572-0241.2006.00681.x. Epub 2006 Jul 18.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验